Zoetis Inc.
ZTS
Positions held
Your positionsZTS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Zoetis Inc. operates in a competitive healthcare sector with a strong focus on animal health, positioning itself as a leader in specialty and generic drug manufacturing.
- Revenue increased by 9% compared to the prior quarter, reaching $2.5 billion.
- Operating margin expanded to 40.5%, indicating improved efficiency.
- The company's debt-to-equity ratio stands at 293.996, suggesting high leverage which may pose risks in economic downturns.
- Zoetis reported a revenue growth of -0.2%, indicating potential challenges in maintaining sales momentum.
- The overall score indicates a 'Sell' signal with a score of -10.00, reflecting negative market sentiment.
Fundamentals
| Market cap | $30.20B | Enterprise value | $37.78B | Trailing P/E | 12.02 | Forward P/E | 11.17 |
| PEG | 6.66 | Price / book | — | Beta | 0.74 | Dividend yield | 2.90% |
| Revenue growth | -0.2% | Earnings growth | 1.2% | Gross margin | 71.7% | Operating margin | 40.7% |
| Profit margin | 27.7% | ROE | 64.9% | ROA | 15.4% | Debt / equity | 2.94 |
| Current ratio | 3.08 | Free cash flow | $2.02B | Analyst recommendation | buy | Mean target | $96.00 |
| 52w high | $148.30 | 52w low | $68.77 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.3B | $2.4B | $2.4B | $2.5B | — |
| Op margin | 40.5% | 36.3% | 34.6% | 39.0% | 40.3% | — |
| Net income | $691M | $601M | $603M | $721M | $726M | — |
| Gross margin | 72.7% | 71.7% | 70.2% | 71.5% | 73.2% | — |
| Gross profit | $1.8B | $1.6B | $1.7B | $1.7B | $1.8B | — |
| Operating income | $999M | $822M | $826M | $936M | $997M | — |
- Revenue +9% vs prior quarter ($2.5B vs $2.3B).
- Gross margin 72.7% (was 71.7% prior quarter).
- Operating margin expanded to 40.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $9.5B | $9.3B | $8.5B | $8.1B |
| Op margin | 38.0% | 36.6% | 35.9% | 36.2% |
| Net income | $2.7B | $2.5B | $2.3B | $2.1B |
| Gross margin | 71.8% | 70.6% | 70.0% | 69.6% |
| Gross profit | $6.8B | $6.5B | $6.0B | $5.6B |
| Operating income | $3.6B | $3.4B | $3.1B | $2.9B |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Zoetis Declares Fourth Quarter 2026 Dividend
2026-10-08 · Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm
2026-10-08 · Is it the Right Time to Add Phibro Stock to Your Portfolio?
2026-10-07 · These 7 major S&P 500 stocks need to rally at least 200% to reclaim their peaks
2026-10-07 · Neogen Soars 4% as Q1 Revenue Beat and Raised Guidance Show “Encouraging Progress”
2026-10-06 · Michael Burry Warns of Risks for These Stocks
2026-10-02 · Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?
2026-10-01 · Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
2026-09-24 · Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-09-24 · Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results
Price (daily)
Full chart · RSI · MACD · patterns